SGC-CHDI patent-free partnership selected as an 'Innovator' presenter at 'Partnering for Cures' meeting in New York, November 16-18, 2014.

The SGC-CHDI open access patent-free partnership for Huntington’s disease research has been selected as a featured Innovator to present on November 17th at the 6th annual Partnering for Cures meeting in New York City, NY. The conference will bring together nearly 1,000 medical research leaders, investors and decision-makers to forge the collaborations needed to speed and improve outcomes-driven R&D.

Ryan Schoenfeld, Director of Medicinal Chemistry at CHDI, will join SGC’s Director Aled Edwards to present the objectives of the partnership and explain how open access plays a major role in accelerating the rate of discovery and knowledge dissemination. The partnership’s unique patent-free approach was recently highlighted in a Nature Medicine News article: Patent-free pact pushes the boundaries of precompetitive research

Partnering for Cures is convened by FasterCures, a D.C.-based center of the Milken Institute. The meeting is focused on bringing together organizations that are committed to innovation, science, and collaboration and features panels that spotlight solutions to long-standing challenges in medical research. SGC-CHDI partnership is one of 30 innovators selected through a competitive proposal process. Each partnership is aimed at reducing the time and cost of getting new medical solutions from discovery to patients.

SGC seeks to replicate this model of open access partnership with other disease groups interested in collaborating to accelerate research and discovery for a cure. 

glqxz9283 sfy39587stf02 mnesdcuix8